CCA
GILD icon

Cypress Capital Advisors’s Gilead Sciences GILD Stock Holding History

Cypress Capital Advisors’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$277K Hold
1,984
– – 0.15% 64
2025
Q4 		$244K Buy
1,984
+12
+0.6% +$1.46K 0.13% 67
2025
Q3 		$219K Buy
1,972
+166
+9% +$18.9K 0.12% 71
2025
Q2 		$200K Buy
+1,806
New +$192K 0.13% 72

Other funds holding GILD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Cypress Capital Advisors's GILD Position: Q1 2026 in Review

Cypress Capital Advisors held its Gilead Sciences (GILD) position steady in Q1 2026 at 1,984 shares worth $277K. The position accounts for 0.15% of the portfolio, ranked #64.

Cypress Capital Advisors first reported a position in GILD in Q2 2025 and has held it in 4 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Cypress Capital Advisors held 1,984 shares of Gilead Sciences worth $277K as of Q1 2026.
  • Cypress Capital Advisors left its Gilead Sciences share count unchanged in Q1 2026.
  • Gilead Sciences made up 0.15% of Cypress Capital Advisors's portfolio in Q1 2026, its #64 holding.
  • Cypress Capital Advisors first reported a position in Gilead Sciences in Q2 2025 and has held it in 4 quarters since.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Cypress Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.